Trimmed co-pays can help companies save money
ORLANDO, Fla. — Companies that lower co-payments on prescription drugs while promoting disease management can lower their own healthcare costs, according to a three-year study commissioned by the Florida Health Care Coalition and published in the journal Health Affairs.
The study, which focused on patients with diabetes, found that companies combining disease-management programs with “value-based insurance design” can earn a return of $1.33 for every dollar they spend upfront on medication.
“Amid soaring healthcare costs, this validates that old saying that an ounce of prevention is worth a pound of cure, and that’s especially true where it often hurts most: in our pocketbooks,” FHCC president and CEO Becky Cherney said.
AxiumPortal.com provides patients with convenient service
LAKE MARY, Fla. — Specialty pharmacy provider Axium Healthcare Pharmacy has launched an online portal to complement its services, the company said Wednesday.
AxiumPortal.com allows patients to manage their accounts, request refills, make co-payments, set reminders and perform other functions.
“The technology is a tool that provides convenience and service on-demand,” Axium president and CEO Mark Montgomery said. “We can stay connected with patients 24/7/365 while providing the company a strong platform to scale the business model.”
The company said it also has plans to make the site usable by physicians, manufacturers, payers, distributors and others.
“Healthcare information systems are the future of health care in America,” Montgomery said. “AxiumPortal.com is another prime example of the capability Axium has within our industry.”
K-V: FDA will approve Gestiva by PDUFA date
ST. LOUIS — K-V Pharmaceutical announced Wednesday that the Food and Drug Administration extended its Prescription Drug User Fee Act action date to April 13 for a drug under development for preventing preterm birth.
K-V, which acquired the injected drug Gestiva (hydroxyprogesterone caproate) from Hologic in 2008, said Hologic originally had been told the FDA would take action Thursday.
K-V said it was confident the drug would receive approval and that the FDA would take action on or before the new PDUFA date.